International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
about
The evolution of anticoagulant therapyAnticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the ArtVenous thromboembolism in cancer patients: an underestimated major health problemSyntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion.Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report.Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinuxVenous thromboembolic prophylaxis after a hepatic resection: patterns of care among liver surgeons.Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization.Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study.Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.The Treatment of Venous Thromboembolism in Patients with Cancer.Controversies in the management of cancer-associated thrombosis.Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort.Acupuncture safety in patients receiving anticoagulants: a systematic review.Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.Inferior vena cava filters: current best practices.Implementing thrombosis guidelines in cancer patients: a review.Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study.Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection.Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: A randomized, controlled trial.Postoperative Massive Pulmonary Embolism Due to Superficial Vein Thrombosis of the Upper LimbAssessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodologyPotential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemiaDistinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patientsEarly venous thromboembolic events are associated with worse prognosis in patients with lung cancer.Impact of a dedicated cancer-associated thrombosis service on clinical outcomes: a mixed-methods evaluation of a clinical improvement exercise.New oral anticoagulants and the cancer patient.Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism.Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients.Venous thromboembolism in children with cancer - a population-based cohort study.Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study
P2860
Q26771859-C588AB41-9465-42D2-B1F4-C5433D2D6863Q26776112-3E3614C9-4658-4471-8EF7-EF340C304FE8Q26852015-BA3823B8-F127-4DD3-91B2-254FC8D6B52FQ30590837-0C32535F-34E0-4CE7-A111-B48D5F54FBEAQ33166582-DB9356E3-3248-4A99-B7EB-8340FA7FE803Q33410578-C6FBD2C5-5A8C-4306-9910-B620B084B2BBQ33415676-9E377435-0EFC-4EEF-9DAF-0AC87B3B4F05Q33416407-B532CB69-E842-4381-8295-DD67D61CF309Q33417504-2B371005-0970-4C92-BB8B-9B3C84090127Q33429840-1FCD4BBC-880F-4F5C-AEE1-04EC2C640C73Q33434346-CCA996FC-C1CD-4FB4-8DAB-179B5EB9C5E2Q33435329-1976B87C-088F-4437-8487-E4F7EB35B7A4Q33436975-03A47B6F-6F31-48DF-9BBD-6A91037D67C7Q33440816-039AA89A-2FB3-4ED1-A6F3-777922FEB017Q33686796-B4DF06F1-B879-46E4-A85F-28A6FF1131EAQ33735646-D759F28C-BB29-4E1A-92FA-B0841C6916F3Q34436061-E6AA1464-AAAF-4F5F-8176-B4F988E417A8Q34462703-719B005A-0B06-4E42-A0E5-C971E2847815Q34463482-EB3BF286-52F3-40EA-BE0E-D09B8D1FD2B2Q34721483-D0AAB715-B2BB-420D-8C76-A1AB74F1BCC6Q34893956-2710FBA6-FAEC-4D6E-A26D-12D3626B1FE7Q35142746-82BFE3EA-E954-408E-8F6D-BAE31072146BQ35174604-ADDD1EF0-17F8-4908-A511-6136E2714FC1Q35683869-286D7450-0AC9-4BE4-8325-B0AF39C26AD9Q36163379-446155B2-866D-4D9D-8AD0-219F076FCF91Q36195033-A9C8044A-2EEA-45F7-B48E-F4335355EA56Q36281232-64FE755E-FD16-46E2-9E54-1BC991464FDDQ36658562-7C86C901-AF3D-4E95-A895-A962A3A4CF65Q36779739-876D4C12-9762-4B6C-9136-3E1FA9CB6751Q36839479-01AC766F-355E-4F01-8EE1-252C64A59799Q37152911-BC2C78DD-BADD-4CEA-A2D1-B5879598CC3EQ37216645-E6E1EDC8-84B5-43B8-AA3A-C00C49BB741EQ37304305-7C6C9909-D2A9-4BCC-98A9-715BE17D31DAQ37516663-7CC8EAB4-91B9-4DAD-951E-40C2F78CD805Q37519054-D34C54DE-7BD2-41D2-81C6-217167552B4CQ37587205-A0E09D24-7264-4B2A-ACE7-6EC22EA5D7D0Q37588677-1C3AD815-442C-41A8-BF52-DA6BD6643B7EQ37669093-CCC736B5-A513-42A3-BD02-1CB6F47671E7Q37672276-EF029E60-BF23-411C-ADCC-20804B9687A4Q37702182-E7ED0885-7B4C-4782-B49F-D297858AD284
P2860
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
International clinical practic ...... olism in patients with cancer.
@ast
International clinical practic ...... olism in patients with cancer.
@en
type
label
International clinical practic ...... olism in patients with cancer.
@ast
International clinical practic ...... olism in patients with cancer.
@en
prefLabel
International clinical practic ...... olism in patients with cancer.
@ast
International clinical practic ...... olism in patients with cancer.
@en
P2093
P50
P356
P1476
International clinical practic ...... bolism in patients with cancer
@en
P2093
A K Kakkar
D Brilhante
G T Gerotzafias
H Bounameaux
H R Büller
I Pabinger
P356
10.1111/JTH.12070
P577
2013-01-01T00:00:00Z